SCHEMBL5072278

SCHEMBL5072278

CCCCn1c(CN(Cc2ccccc2)Cc2ccccc2)cnc1-c1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.51
HSD11B1 P28845 2/20 0.44
NR1H3 Q13133 1/20 0.40
PDE4B Q07343 2/20 0.39
KDM4E B2RXH2 2/20 0.39
HSD17B10 Q99714 2/20 0.39
ADORA2B P29275 1/20 0.39
C5AR1 P21730 1/20 0.39
ALDH1A1 P00352 2/20 0.38
HPGD P15428 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.37
LMNA P02545 2/20 0.37
HTT P42858 2/20 0.37
MAPK1 P28482 1/20 0.37
MAOB P27338 2/20 0.37
ALOX12 P18054 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
BCHE P06276 1/20 0.36
ACHE P22303 1/20 0.36
CYP11B1 P15538 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5070162 0.95 TSHR (0.47) TSHRHSD11B1NR1H3PDE4BKDM4E
SCHEMBL5137319 0.95 TSHR (0.47) TSHRHSD11B1NR1H3PDE4BKDM4E
SCHEMBL5134965 0.94 HSD11B1 (0.48) TSHRHSD11B1NR1H3PDE4BKDM4E
SCHEMBL14415648 0.94 TSHR (0.46) TSHRHSD11B1NR1H3PDE4BKDM4E
SCHEMBL5134980 0.94 HSD11B1 (0.54) TSHRHSD11B1C5AR1BCHE
SCHEMBL1912760 0.94 TSHR (0.48) TSHRHSD11B1NR1H3PDE4BKDM4E
SCHEMBL5136036 0.93 TSHR (0.45) TSHRHSD11B1NR1H3PDE4BKDM4E
SCHEMBL5136484 0.93 TSHR (0.45) TSHRHSD11B1NR1H3PDE4BKDM4E
SCHEMBL5137316 0.93 TSHR (0.45) TSHRHSD11B1NR1H3PDE4BKDM4E
SCHEMBL5137360 0.93 TSHR (0.45) TSHRHSD11B1NR1H3PDE4BKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed